Fig. 4From: Malignant pleural mesothelioma: treatment patterns and humanistic burden of disease in EuropeMean EQ-5D UI (A) and mean EQ-5D VAS scores (B) of MPM patients, stratified by current treatment and by current line of therapy at time of data abstraction. Note: Patients from EU countries including France, Germany, Italy, Spain, and the UK. Error bars represent 95% confidence intervals. The MID for the EQ-5D UI score is 0.08 points, and the MID for the EQ-5D VAS score is 7 points. BSC, best supportive care; doublet, doublet chemotherapy; EQ-5D, European quality of lifeā5 dimensions; UI, utility index; LOT, line of therapy; MID, minimally important difference; MPM, malignant pleural mesothelioma; others, other therapies; SACT, systemic anti-cancer therapy; triplet, triplet chemotherapy; VAS, visual analogue scale; 1āL, first-line therapy; 1āL-M, first-line maintenance therapy; 2āLā+āSACT, SACT at second or later lines; 2āL+ BSC, BSC at second or later linesBack to article page